Shandong Pharmaceutical Glass Co.Ltd (SHA:600529)
China · Delayed Price · Currency is CNY 18.37
+0.11 (0.60%)
Mar 27, 2026, 1:05 PM CST
SHA:600529 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,414 | 4,845 | 4,937 | 4,130 | 3,820 |
Other Revenue | 60.01 | 59.56 | 45.68 | 56.82 | 55.53 |
| 4,474 | 4,905 | 4,982 | 4,187 | 3,875 | |
Revenue Growth (YoY) | -8.79% | -1.55% | 18.98% | 8.05% | 13.08% |
Cost of Revenue | 3,088 | 3,339 | 3,618 | 3,090 | 2,789 |
Gross Profit | 1,386 | 1,566 | 1,364 | 1,098 | 1,086 |
Selling, General & Admin | 338.72 | 341.62 | 332.17 | 251.59 | 230.19 |
Research & Development | 174.8 | 151.76 | 137.95 | 138.94 | 135.63 |
Other Operating Expenses | 43.2 | 39.06 | 33.84 | 32.03 | 31.19 |
Operating Expenses | 552.14 | 534.56 | 515.37 | 434.56 | 407.88 |
Operating Income | 833.67 | 1,031 | 848.58 | 662.95 | 678.38 |
Interest Expense | -0.51 | -0.03 | -0.23 | -0.26 | -0.28 |
Interest & Investment Income | 33.11 | 35.77 | 44.11 | 16.74 | 17.47 |
Currency Exchange Gain (Loss) | 4.28 | 17.22 | 13.01 | 31.5 | -9.48 |
Other Non Operating Income (Expenses) | -3.71 | -2.36 | -2.8 | -0.2 | -2.44 |
EBT Excluding Unusual Items | 866.84 | 1,082 | 902.67 | 710.73 | 683.64 |
Gain (Loss) on Sale of Investments | 9.14 | 24.46 | 22.83 | 3.73 | 9.26 |
Gain (Loss) on Sale of Assets | -4.3 | -1.33 | -12.24 | -3.51 | -22.7 |
Asset Writedown | -53.79 | -5.09 | -12.88 | -16.96 | -11.61 |
Other Unusual Items | 12.95 | 10.74 | 10.44 | 14.06 | 30.13 |
Pretax Income | 830.83 | 1,111 | 910.82 | 708.05 | 688.72 |
Income Tax Expense | 141.2 | 167.81 | 135.02 | 89.76 | 97.63 |
Earnings From Continuing Operations | 689.63 | 942.99 | 775.8 | 618.29 | 591.09 |
Net Income | 689.63 | 942.99 | 775.8 | 618.29 | 591.09 |
Net Income to Common | 689.63 | 942.99 | 775.8 | 618.29 | 591.09 |
Net Income Growth | -26.87% | 21.55% | 25.48% | 4.60% | 4.72% |
Shares Outstanding (Basic) | 663 | 664 | 663 | 600 | 597 |
Shares Outstanding (Diluted) | 663 | 664 | 663 | 600 | 597 |
Shares Change (YoY) | -0.15% | 0.15% | 10.46% | 0.54% | 0.49% |
EPS (Basic) | 1.04 | 1.42 | 1.17 | 1.03 | 0.99 |
EPS (Diluted) | 1.04 | 1.42 | 1.17 | 1.03 | 0.99 |
EPS Growth | -26.76% | 21.37% | 13.59% | 4.04% | 4.21% |
Free Cash Flow | 345.06 | 517.27 | 376.45 | -458.27 | -58.82 |
Free Cash Flow Per Share | 0.52 | 0.78 | 0.57 | -0.76 | -0.10 |
Dividend Per Share | 0.460 | 0.620 | 0.400 | 0.300 | 0.300 |
Dividend Growth | -25.81% | 55.00% | 33.33% | - | - |
Gross Margin | 30.98% | 31.93% | 27.38% | 26.21% | 28.03% |
Operating Margin | 18.63% | 21.03% | 17.03% | 15.83% | 17.51% |
Profit Margin | 15.41% | 19.23% | 15.57% | 14.77% | 15.25% |
Free Cash Flow Margin | 7.71% | 10.55% | 7.56% | -10.94% | -1.52% |
EBITDA | 1,223 | 1,417 | 1,174 | 958.13 | 919.03 |
EBITDA Margin | 27.33% | 28.88% | 23.56% | 22.88% | 23.71% |
D&A For EBITDA | 389.26 | 385.15 | 325.13 | 295.17 | 240.64 |
EBIT | 833.67 | 1,031 | 848.58 | 662.95 | 678.38 |
EBIT Margin | 18.63% | 21.03% | 17.03% | 15.83% | 17.51% |
Effective Tax Rate | 16.99% | 15.11% | 14.82% | 12.68% | 14.17% |
Revenue as Reported | 4,474 | 4,905 | 4,982 | 4,187 | 3,875 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.